Skip to main content
    O

    Ovid Therapeutics Inc (OVID)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.40
    -0.14 (-5.51%)

    Market Cap: $479.38M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ovid Therapeutics Inc (OVID) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Ovid Therapeutics (OVID) trades at 335.8x sales and 2.5x book value. Its P/B of 2.5x is above its 5-year median of 1.3x. Its forward P/E is 1.8x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E1.8x
    Price to sales335.8x
    Price to book2.5x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 47.1% above 1.7x.

    MultipleCurrent5-year median10-year median
    P/B2.5x1.3x1.7x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 109 months (10-year).

    Valuation History

    Over the 5 of the 9 year ends shown that have a P/S, its P/S ranged from 11.2x in 2020 to 580.0x in 2023.

    Year endPriceP/EP/SP/B
    2025$1.63N/A16.2x1.0x
    2024$0.93N/A117.0x1.0x
    2023$3.22N/A580.0x2.6x
    2022$1.86N/A87.1x1.0x
    2021$3.211.6xN/A1.2x
    2020$2.31N/A11.2x3.4x
    2019$4.15N/AN/A2.9x
    2018$2.42N/AN/A1.5x
    2017$9.87N/AN/A2.9x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    Frequently Asked Questions About OVID

    What is OVID's forward P/E ratio?

    Ovid Therapeutics has a forward P/E ratio of 1.8x.

    What is OVID's price to sales ratio?

    Ovid Therapeutics has a price to sales ratio of 335.8x.